Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

7(87.5%)

N/A

1(12.5%)

8Total

Phase 2(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05557318Not ApplicableRecruiting

Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge

Role: collaborator

NCT00695019Phase 2Completed

Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

Role: lead

NCT01146535Phase 2Completed

Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

Role: lead

NCT00690885Phase 2Terminated

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Role: lead

NCT01442779Phase 2Completed

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

Role: collaborator

NCT00895947Phase 2Completed

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Role: lead

NCT00454181Phase 2Completed

Treatment of Oral Warts in HIV+ Patients

Role: lead

NCT00483184Phase 2Completed

Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease

Role: collaborator

All 8 trials loaded